中国医药
中國醫藥
중국의약
CHINA MEDICINE
2015年
5期
623-625
,共3页
李建明%张杰%史忠良%郑冬芳%陈刚%江旭峰%魏华%张医
李建明%張傑%史忠良%鄭鼕芳%陳剛%江旭峰%魏華%張醫
리건명%장걸%사충량%정동방%진강%강욱봉%위화%장의
心绞痛,不稳定型%红景天属%肝素,低分子量
心絞痛,不穩定型%紅景天屬%肝素,低分子量
심교통,불은정형%홍경천속%간소,저분자량
Angina,unstable%Rhodiola%Heparin,low-molecular-weight
目的 观察大株红景天注射液联合低分子肝素治疗不稳定型心绞痛(UAP)的临床效果及安全性.方法 选择2012年1月至2014年5月解放军第八六医院收治的UAP患者100例,完全随机分为观察组(50例)和对照组(50例).对照组给予常规和对症治疗;观察组在常规和对症治疗基础上加用大株红景天注射液联合低分子肝素治疗.观察2组治疗7d后临床疗效、心绞痛发作频次与持续时间、心电图改善情况.结果 观察组患者总有效率高于对照组,2组比较差异有统计学意义[92.0%(46/50)比72.0%(36/50),P<0.05].观察组心绞痛发作频次:治疗前(16.7±1.2)次/周,治疗后(3.8±0.5)次/周;发作持续时间:治疗前(15.2 ±2.9) min,治疗后(4.5±0.7) min.对照组心绞痛发作频次:治疗前(16.8±1.4)次/周,治疗后(7.7±1.2)次/周;发作持续时间:治疗前(14.9±3.5) min,治疗后(6.9 ±0.9) min.上述指标2组间治疗后比较差异有统计学意义(P<0.05).观察组患者心电图改善率为48.0%(24/50),对照组为24.0%(12/50),2组比较差异有统计学意义(P<0.05).结论 大株红景天注射液联合低分子肝素治疗UAP可改善心绞痛症状,缩短心绞痛发作持续时间,且安全有效.
目的 觀察大株紅景天註射液聯閤低分子肝素治療不穩定型心絞痛(UAP)的臨床效果及安全性.方法 選擇2012年1月至2014年5月解放軍第八六醫院收治的UAP患者100例,完全隨機分為觀察組(50例)和對照組(50例).對照組給予常規和對癥治療;觀察組在常規和對癥治療基礎上加用大株紅景天註射液聯閤低分子肝素治療.觀察2組治療7d後臨床療效、心絞痛髮作頻次與持續時間、心電圖改善情況.結果 觀察組患者總有效率高于對照組,2組比較差異有統計學意義[92.0%(46/50)比72.0%(36/50),P<0.05].觀察組心絞痛髮作頻次:治療前(16.7±1.2)次/週,治療後(3.8±0.5)次/週;髮作持續時間:治療前(15.2 ±2.9) min,治療後(4.5±0.7) min.對照組心絞痛髮作頻次:治療前(16.8±1.4)次/週,治療後(7.7±1.2)次/週;髮作持續時間:治療前(14.9±3.5) min,治療後(6.9 ±0.9) min.上述指標2組間治療後比較差異有統計學意義(P<0.05).觀察組患者心電圖改善率為48.0%(24/50),對照組為24.0%(12/50),2組比較差異有統計學意義(P<0.05).結論 大株紅景天註射液聯閤低分子肝素治療UAP可改善心絞痛癥狀,縮短心絞痛髮作持續時間,且安全有效.
목적 관찰대주홍경천주사액연합저분자간소치료불은정형심교통(UAP)적림상효과급안전성.방법 선택2012년1월지2014년5월해방군제팔륙의원수치적UAP환자100례,완전수궤분위관찰조(50례)화대조조(50례).대조조급여상규화대증치료;관찰조재상규화대증치료기출상가용대주홍경천주사액연합저분자간소치료.관찰2조치료7d후림상료효、심교통발작빈차여지속시간、심전도개선정황.결과 관찰조환자총유효솔고우대조조,2조비교차이유통계학의의[92.0%(46/50)비72.0%(36/50),P<0.05].관찰조심교통발작빈차:치료전(16.7±1.2)차/주,치료후(3.8±0.5)차/주;발작지속시간:치료전(15.2 ±2.9) min,치료후(4.5±0.7) min.대조조심교통발작빈차:치료전(16.8±1.4)차/주,치료후(7.7±1.2)차/주;발작지속시간:치료전(14.9±3.5) min,치료후(6.9 ±0.9) min.상술지표2조간치료후비교차이유통계학의의(P<0.05).관찰조환자심전도개선솔위48.0%(24/50),대조조위24.0%(12/50),2조비교차이유통계학의의(P<0.05).결론 대주홍경천주사액연합저분자간소치료UAP가개선심교통증상,축단심교통발작지속시간,차안전유효.
Objective To observe the clinical efficacy and safety of Soften injection combined with low molecular weight heparin in treatment of unstable angina pectoris (UAP).Methods A total of 100 patients with UAP from January 2012 to May 2014 were enrolled and randomly divided into observation group (50 cases) and control group (50 cases).All the patients received conventional and symptomatic treatment;the patients in observation group were additionally administrated with sofren injection combined with low molecular weight hepa rin.The clinical curative effect,frequency and duration of angina attack,ECG improvement were assessed and compared between two groups 7 days after treatment.Results The clinical efficacy of observation group was significantly higher than that of control group [92.0% (46/50) vs 72.0% (36/50),P < 0.05].Before treatment,the frequency and duration of angina attack was (16.7 ± 1.2) times per week and (15.2 ± 2.9) min in observe group;it was (16.8 ± 1.4) times per week and (14.9 ± 3.5) min in control group.After treatment,the angina attack frequency and duration was (3.8 ± 0.5) times per week and (4.5 ± 0.7) min in observe group,which were both significantly lower than those in control group [(7.7 ± 1.2) times per week and (6.9 ± 0.9) min,respectively,both P < 0.05].The improvement rate of ECG in observe group was statistical higher than that in control group [48.0 (24/50) vs 24.0% (12/50),P < 0.05].Conclusion Sofren injection combined with low molecular weight heparin can effectively and safely improve the angina symptoms and shorten the attack duration in treatment of UAP.